Economic analysis of celecoxib versus diclofenac plus omeprazole for the treatment of arthritis in patients at risk of ulcer disease
تعليق: إقتصاديات إستخدام الأوميبراز في الصين في المرضى عاليي الخطورة.--احمد شوقي محمدين 20:17، 22 أكتوبر 2016 (ت ع م)
في الأسفل روابط ذات صلة عن نفس الموضوع.
روابط ذات صلة[عدل]
مقالات مهمة جدا[عدل]
- THERAPEUTIC SUBSTITUTION POST-PATENT EXPIRY: THE CASES OF ACE INHIBITORS AND PROTON PUMP INHIBITORS حجم مكسب 40 مليار سنوياً
- A systematic review of the economic evaluations of the different proton pump inhibitors (PPIs) marketed in Spain
مقالات مهمة[عدل]
- Cost-effectiveness analysis of proton pump inhibitors compared to omeprazole in the healing of reflux oesophagitis
- http://www.tandfonline.com/doi/abs/10.3111/200505025038
- https://www.researchgate.net/publication/232070514_Cost-effectiveness_analysis_of_proton_pump_inhibitors_compared_to_omeprazole_in_the_healing_of_reflux_oesophagitis
- Arthritis treatment in Hong Kong--cost analysis of celecoxib versus conventional NSAIDS, with or without gastroprotective agents.
- https://www.ncbi.nlm.nih.gov/pubmed/12452942
- A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling
- https://www.ncbi.nlm.nih.gov/pubmed/17018227
- A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis
- https://www.ncbi.nlm.nih.gov/pubmed/11280104
- Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial.
- https://www.ncbi.nlm.nih.gov/pubmed/15480981 من مجلة إقتصاديات الصيدلة
- Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis
- من مجلة نيو إنجلند جورنال أوف ميديسين
- A pharmacoeconomic comparison of the efficacy and costs of pantoprazole and omeprazole for the treatment of peptic ulcer or gastroesophageal reflux disease in The Netherlands.
- https://www.ncbi.nlm.nih.gov/pubmed/12749518
- Omeprazole: a pharmacoeconomic evaluation of its use in duodenal ulcer and reflux oesophagitis.
- https://www.ncbi.nlm.nih.gov/pubmed/10146883
المقالة الحالية[عدل]
Aliment Pharmacol Ther. 2003 Jul 15;18(2):217-22.
Economic analysis of celecoxib versus diclofenac plus omeprazole for the treatment of arthritis in patients at risk of ulcer disease.
Lee KK1, You JH, Ho JT, Suen BY, Yung MY, Lau WH, Lee VW, Sung JY, Chan FK.
Abstract
AIM:
To evaluate the economic impact of celecoxib therapy vs. diclofenac plus omeprazole therapy for the treatment of arthritis in Chinese patients with a high risk of bleeding, from the perspective of a public health organization in Hong Kong. METHODS: The medical records of 287 Chinese arthritic patients with a history of bleeding ulcers who had previously participated in a randomised study of celecoxib 200 mg twice daily and extended-release diclofenac 75 mg twice daily plus 20 mg of omeprazole daily for 6 months were reviewed.
RESULTS:
Compared to the diclofenac plus omeprazole group, the average total direct cost per patient in the celecoxib group showed a significant reduction of 11%, from HK 10,915 (range HK dollars 10,915-57,899) to HK dollars 9714 (range HK dollars 9714-89,770) (P<0.0001) (1 US dollars=7.8 HK dollars). The median direct medical cost for routine management in the celecoxib group was significantly lower (11%) than that for the diclofenac plus omeprazole group [HK dollars 10,915 (range 10,915-28,048) vs. HK dollars 9714 (range HK dollars 6946-26,179) (P<0.0001)]. In patients who experienced recurrent bleeding, the celecoxib group showed a significantly higher median cost of management of recurrent bleeding than the diclofenac plus omeprazole group [HK dollars 8466 (range 572-29,851) vs. HK dollars 23,210 (range HK dollars 12,318-65,823)] (P=0.036).
CONCLUSIONS:
Celecoxib therapy appears to cost less compared with diclofenac plus omeprazole for treatment of arthritis in Chinese patients with a high risk of bleeding.
PMID: 12869082
